Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
TEMPLE CITY, Calif., April 25, 2017 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that its first quarter 2017 financial results will be released after market close on Monday, May 8, 2017. The company’s Chairman and Chief Executive Officer Ming Hsieh, its Chief Science Officer Dr. Harry Gao, and its Chief Financial Officer Paul Kim will host a conference call for the investment community the same day at 5:00 PM ET (2:00 PM PT) to discuss the results and answer questions.
The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 4012282. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 4012282 through May 15, 2017.
About Fulgent Genetics
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 300 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts: The Blueshirt Group Nicole Borsje, 415-217-2633, [email protected] Chris Danne, 415-217-5865, [email protected]
